For Research Use Only

## TRAIL Polyclonal antibody Catalog Number: 27064-1-AP Featured Product

Featured Product






Basic Information	Catalog Number: 27064-1-AP	GenBank Accessi BC032722	on Number:	Purification Method: Antigen affinity purification	
	Size:	GenelD (NCBI):		Recommended Dilutions:	
	500 ug/ml	Durce: UNIPROT ID:		WB 1:500-1:3000 IHC 1:50-1:500 IF/ICC 1:50-1:500	
	Source: Rabbit				
	Isotype:				
	IgG	tumor necrosis fa			
	Immunogen Catalog Number: AG25746	superfamily, member 10 Calculated MW:			
	AU25740	281 aa, 33 kDa			
Applications	Tested Applications:	Positive Controls:			
	WB, IHC, IF/ICC, ELISA	WB: human milk, Cited Applications:			
	WB, IHC, IF	ITL : numan kigney tissue, numai		kidney tissue, human lymphoma tissu	
	Species Specificity: IF/ICC : MCF-7 cells, human				
	Cited Species: human, mouse				
	Note-IHC: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0				
	TRAIL, also known as CD253 or TNFSF10 (tumor necrosis factor superfamily member 10), is a typical death ligand expressed on natural killer cells and cytotoxic T lymphocytes. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. TRAIL induces apoptotic cell death in cancer by binding to its functional death receptors, death receptor (DR) 4 (TNFRSF10A/TRAIL-R1) and DR5 (TNFRSF10B/TRAIL-R2) to activate the extrinsic apoptosis pathway. TRAIL also activates c-Jun N-terminal kinase (MAPK8/JNK) and the transcription factor nuclear factor- κ E (NF κ B). The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3.				
Background Information	expressed on natural killer cells a transformed and tumor cells, but o in most normal tissues. TRAIL ind death receptor (DR) 4 (TNFRSF 10A pathway. TRAIL also activates c-J (NF & B). The binding of this prote	and cytotoxic T lympho does not appear to kill uces apoptotic cell dea A/TRAIL-R1) and DR5 (1 un N-terminal kinase (	ocytes. This protei normal cells althorath in cancer by bi INFRSF10B/TRAIL- (MAPK8/JNK) and 1	n preferentially induces apoptosis in ough it is expressed at a significant lev- nding to its functional death receptors, R2) to activate the extrinsic apoptosis he transcription factor nuclear factor- κ	
	expressed on natural killer cells a transformed and tumor cells, but o in most normal tissues. TRAIL ind death receptor (DR) 4 (TNFRSF10A pathway. TRAIL also activates c-J (NF × B). The binding of this prote 8, and caspase 3.	and cytotoxic T lympho does not appear to kill uces apoptotic cell dea A/TRAIL-R1) and DR5 (1 un N-terminal kinase ( in to its receptors has l	ocytes. This protei normal cells altho ath in cancer by bi INFRSF 10B/TRAIL- (MAPK8/JNK) and 1 been shown to trig	n preferentially induces apoptosis in ough it is expressed at a significant leven nding to its functional death receptors, R2) to activate the extrinsic apoptosis the transcription factor nuclear factor- & ger the activation of MAPK8/JNK, caspa	
Background Information	expressed on natural killer cells a transformed and tumor cells, but of in most normal tissues. TRAIL ind death receptor (DR) 4 (TNFRSF 10A pathway. TRAIL also activates c-J (NF $\ltimes$ B). The binding of this prote 8, and caspase 3.	and cytotoxic T lympho does not appear to kill uces apoptotic cell dea (/TRAIL-R1) and DR5 (T un N-terminal kinase ( in to its receptors has I Pubmed ID Jo	ocytes. This protei normal cells altho ath in cancer by bi INFRSF 10B/TRAIL- (MAPK8/JNK) and 1 been shown to trig	n preferentially induces apoptosis in ough it is expressed at a significant leven nding to its functional death receptors, R2) to activate the extrinsic apoptosis he transcription factor nuclear factor- $\kappa$	
	expressed on natural killer cells a transformed and tumor cells, but a in most normal tissues. TRAIL ind death receptor (DR) 4 (TNFRSF10A pathway. TRAIL also activates c-J (NF × B). The binding of this prote 8, and caspase 3. Author F Xiao-Jie Chen	and cytotoxic T lympho does not appear to kill uces apoptotic cell dea (/TRAIL-R1) and DR5 (1 un N-terminal kinase ( in to its receptors has l Pubmed ID Jo 36256535 J M	ocytes. This protei normal cells altho ath in cancer by bi INFRSF 10B/TRAIL- (MAPK8/JNK) and to been shown to trig urnal Nat Prod	n preferentially induces apoptosis in ough it is expressed at a significant leven nding to its functional death receptors, R2) to activate the extrinsic apoptosis the transcription factor nuclear factor- * ger the activation of MAPK8/JNK, caspa	
	expressed on natural killer cells a transformed and tumor cells, but o in most normal tissues. TRAIL ind death receptor (DR) 4 (TNFRSF10A pathway. TRAIL also activates c-J (NF × B). The binding of this prote 8, and caspase 3. Author F Xiao-Jie Chen E Li Zhang	and cytotoxic T lympho does not appear to kill uces apoptotic cell dea \/TRAIL-R1) and DR5 (T un N-terminal kinase ( in to its receptors has l Pubmed ID Jo 36256535 J N 36265256 Ph	ocytes. This protei normal cells altho ath in cancer by bi INFRSF 10B/TRAIL- (MAPK8/JNK) and 1 been shown to trig	n preferentially induces apoptosis in ough it is expressed at a significant leven nding to its functional death receptors, R2) to activate the extrinsic apoptosis the transcription factor nuclear factor- * ger the activation of MAPK8/JNK, caspa Application WB WB	


For technical support and original validation data for this product please contact: T: 4006900926 E: Proteintech-CN@ptglab.com W: ptgcn.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.


## Selected Validation Data




Human milk sample were subjected to SDS PAGE followed by western blot with 27064-1-AP (TRAIL antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.



Immunohistochemical analysis of paraffinembedded human kidney tissue slide using 27064-1-AP (TRAIL antibody) at dilution of 1:200 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunohistochemical analysis of paraffinembedded human kidney tissue slide using 27064-1-AP (TRAIL antibody) at dilution of 1:200 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunofluorescent analysis of (-20°C Ethanol) fixed MCF-7 cells using 27064-1-AP (TRAIL antibody) at dilution of 1:50 and Alexa Fluor 488conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).